Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

Michael R. Martino, Manuel Gutiérrez-Aguilar, Nicole K.H. Yiew, Andrew J. Lutkewitte, Jason M. Singer, Kyle McCommis, Daniel Ferguson, Kim H.H. Liss, Jun Yoshino, M. Katie Renkemeyer, Gordon Smith, Kevin Cho, Justin A. Fletcher, Samuel Klein, Gary J. Patti, Shawn C. Burgess, Brian N. Finck

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

(Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

Original languageEnglish
Article number111633
JournalCell Reports
Volume41
Issue number7
DOIs
StatePublished - Nov 15 2022

Fingerprint

Dive into the research topics of 'Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))'. Together they form a unique fingerprint.

Cite this